5 Stocks Pushing The Health Services Industry Lower

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 42 points (0.3%) at 14,338 as of Thursday, March 7, 2013, 11:50 AM ET. The NYSE advances/declines ratio sits at 1,674 issues advancing vs. 1,197 declining with 153 unchanged.

The Health Services industry currently sits up 0.2% versus the S&P 500, which is up 0.2%. On the negative front, top decliners within the industry include DaVita HealthCare Partners ( DVA), down 2.6%, and Fresenius Medical Care Corporation ( FMS), down 0.7%. Top gainers within the industry include Universal Health Services ( UHS), up 2.1%, Life Technologies ( LIFE), up 1.8% and Smith & Nephew ( SNN), up 1.2%.

TheStreet Ratings group would like to highlight 5 stocks pushing the industry lower today:

5. ResMed ( RMD) is one of the companies pushing the Health Services industry lower today. As of noon trading, ResMed is down $1.20 (-2.7%) to $43.81 on average volume Thus far, 538,098 shares of ResMed exchanged hands as compared to its average daily volume of 965,500 shares. The stock has ranged in price between $43.65-$44.85 after having opened the day at $44.80 as compared to the previous trading day's close of $45.01.

ResMed Inc., through its subsidiaries, engages in the development, manufacture, and distribution of medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders. ResMed has a market cap of $6.5 billion and is part of the health care sector. The company has a P/E ratio of 22.8, above the S&P 500 P/E ratio of 17.7. Shares are up 8.3% year to date as of the close of trading on Wednesday. Currently there are 4 analysts that rate ResMed a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates ResMed as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full ResMed Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

4. As of noon trading, Quest Diagnostics ( DGX) is down $0.60 (-1.1%) to $55.74 on average volume Thus far, 463,920 shares of Quest Diagnostics exchanged hands as compared to its average daily volume of 1.2 million shares. The stock has ranged in price between $55.69-$56.46 after having opened the day at $56.26 as compared to the previous trading day's close of $56.34.

Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. Quest Diagnostics has a market cap of $8.9 billion and is part of the health care sector. The company has a P/E ratio of 14.4, below the S&P 500 P/E ratio of 17.7. Shares are down 3.3% year to date as of the close of trading on Wednesday. Currently there is 1 analyst that rates Quest Diagnostics a buy, 2 analysts rate it a sell, and 14 rate it a hold.

TheStreet Ratings rates Quest Diagnostics as a buy. The company's strengths can be seen in multiple areas, such as its notable return on equity, good cash flow from operations, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Quest Diagnostics Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

3. As of noon trading, Baxter International ( BAX) is down $0.56 (-0.8%) to $69.42 on light volume Thus far, 672,763 shares of Baxter International exchanged hands as compared to its average daily volume of 2.8 million shares. The stock has ranged in price between $69.35-$70.09 after having opened the day at $69.85 as compared to the previous trading day's close of $69.97.

Baxter International Inc., through its subsidiaries, develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. Baxter International has a market cap of $38.3 billion and is part of the health care sector. The company has a P/E ratio of 16.8, below the S&P 500 P/E ratio of 17.7. Shares are up 5.4% year to date as of the close of trading on Wednesday. Currently there are 12 analysts that rate Baxter International a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Baxter International as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share, increase in net income, revenue growth and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Baxter International Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

2. As of noon trading, Medtronic ( MDT) is down $0.22 (-0.5%) to $45.81 on light volume Thus far, 805,095 shares of Medtronic exchanged hands as compared to its average daily volume of 4.6 million shares. The stock has ranged in price between $45.69-$46.24 after having opened the day at $46.02 as compared to the previous trading day's close of $46.03.

Medtronic, Inc. manufactures and sells device-based medical therapies worldwide. Medtronic has a market cap of $46.3 billion and is part of the health care sector. The company has a P/E ratio of 14.8, below the S&P 500 P/E ratio of 17.7. Shares are up 12.2% year to date as of the close of trading on Wednesday. Currently there are 8 analysts that rate Medtronic a buy, no analysts rate it a sell, and 12 rate it a hold.

TheStreet Ratings rates Medtronic as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share, increase in net income, revenue growth and attractive valuation levels. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Medtronic Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

1. As of noon trading, Intuitive Surgical ( ISRG) is down $9.40 (-1.8%) to $510.38 on heavy volume Thus far, 428,618 shares of Intuitive Surgical exchanged hands as compared to its average daily volume of 492,000 shares. The stock has ranged in price between $505.66-$522.96 after having opened the day at $519.82 as compared to the previous trading day's close of $519.78.

Intuitive Surgical, Inc. designs, manufactures, and markets da Vinci surgical systems, and related instruments and accessories. Intuitive Surgical has a market cap of $21.1 billion and is part of the health care sector. The company has a P/E ratio of 32.9, above the S&P 500 P/E ratio of 17.7. Shares are up 7.2% year to date as of the close of trading on Wednesday. Currently there are 10 analysts that rate Intuitive Surgical a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Intuitive Surgical as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, growth in earnings per share, compelling growth in net income and expanding profit margins. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Intuitive Surgical Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).

A reminder about TheStreet Ratings group: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

null

More from Markets

Replay: Jim Cramer on Tariffs, the Market Rally, Caterpillar and Micron

Replay: Jim Cramer on Tariffs, the Market Rally, Caterpillar and Micron

Video: When Planning for Retirement, Don't Underestimate Your Life Span

Video: When Planning for Retirement, Don't Underestimate Your Life Span

Video: Here's What May Come Next for Theranos Founder and CEO Elizabeth Holmes

Video: Here's What May Come Next for Theranos Founder and CEO Elizabeth Holmes

Charlie Gasparino Says GE Is Reportedly Looking to Slash Its Dividend Again

Charlie Gasparino Says GE Is Reportedly Looking to Slash Its Dividend Again

GE Confirms $11.1 Billion Transportation Merger With Wabtec

GE Confirms $11.1 Billion Transportation Merger With Wabtec